Back in January, Nina Paynter and her colleagues at Brigham and Women's Hospital and Celera published a study that found that evaluating patients' 9p21.3 polymorphism, which is associated with cardiovascular disease, did not improve cardiovascular disease risk classification when added to an assessment of conventional risk factors.